Roadmap — Larasguna

10.1 · High-density launch corridors

Four criteria. All four, or wait.

A region meeting all four is a launch candidate. A region meeting three is a future-phase target.

01

Disease burden

Documented high incidence of the metabolic and maternal conditions the milestones address.

02

Mobile broadband

Enough penetration to sustain session attestation and on-device proof generation.

03

Existing workforce

Accredited community health workers who can be onboarded rather than trained from scratch.

04

Compatible records

A health record infrastructure that fits the gateway specification.

+

Payers over population

A corridor with self-insured employers and a fund already piloting value-based payment moves faster than a larger one without.

+

Accreditation capacity

Professional bodies and informatics programs decide how fast the mesh reaches operating density.

Neighbourhood, not metropolisLaunch concentrates in a few contiguous districts of tier-1 archipelagic metropolises. A validator serving participants scattered over forty kilometres is a mobile clinic, not a neighbourhood presence.

Corridor density — Fig. 10.1Corridor selection and validator density.

10.1–10.3 · Network expansion

From one corridor to neutral infrastructure

Phase I

Archipelagic launch corridors

Dense districts where validator density, participant volume and payer appetite reinforce each other.

Phase II

Sovereign network replication

Corridors that share the launch profile, not its language. Each needs a full readiness assessment; order follows whichever clears first. Core contracts, circuits and registry are reused unchanged.

Phase III

Global preventive layer

Any payer, any jurisdiction, through a certified gateway and validator cohort — one taxonomy, one audit standard, one canonical token.

10.4 · Institutional B2B2C flywheel

Payers fund cohorts, not individuals

So acquisition runs through institutions rather than consumer marketing. Each payer makes the next one's decision easier.

Institution funds a cohort Attestation volume Validator income More validators Coverage & audit capacity A more credible counterparty

Claims reduction

Self-insured employers

Large workforces with documented metabolic burden and benefits enrollment already in place.

Funded follow-through

Diagnostic lab chains

They already run screening campaigns, and can turn a one-off screen into a funded program.

Deepest reach

Community health networks

Municipal and regional networks closest to where preventable admissions concentrate.

B2B2C acquisition flywheel — Fig. 10.4The institutional acquisition flywheel.

10.5 · Cultural localization

A corridor can choose its scheduling defaults. It cannot choose whether a proof requires a bonded validator.

01

Scheduling

Fitted to working hours and commutes, not fixed weekday slots.

02

Dietary guidance

Written around local, affordable foods and reviewed by local nutrition professionals.

03

Observance calendars

Clinically reviewed variations for fasting periods. No milestone ever rewards fasting against clinical advice.

04

Household structure

Family account defaults follow who usually makes health spending decisions — unless the participant overrides.

10.6 · Phase-gate progression

An incomplete stage is never treated as complete

Each gate has entry requirements, mandatory deliverables and pause criteria that halt progression.

A

Infrastructure readiness

Entry: Audited settlement and verification contracts, completed circuit audit, a certified gateway partner and one accreditation pathway.
Deliverables: A working testnet with validator terminal apps, and a Board-approved milestone registry.

Pause ifAny unresolved high-severity audit finding.

B

Controlled service validation

Entry: Gate A, plus a signed payer agreement with real capital in an escrow vault.
Deliverables: A bounded pilot with measured attestation success, audit sensitivity and unit economics.

Pause ifAttestation failure above threshold, or a collusion case where slashing missed its expected outcome.

C

Commercial & protocol readiness

Entry: Gate B, with pilot performance meeting the modeled projections.
Deliverables: Multi-payer programs, public liquidity bootstrapping, a live Economic Chamber and the token generation event in its announced window.

Pause ifPayer commitments fall below what validator economics need at cohort scale.

D

Network replication

Entry: Gate C, plus a completed readiness assessment for corridor two.
Deliverables: Corridor-two activation, a second certified gateway and core reuse without redeployment.

Pause ifReplication economics materially worse than launch, for reasons not specific to the corridor.

Phase-gate map A to D — Fig. 10.6The phase-gate map, from infrastructure readiness to replication.

12 · Systemic risk taxonomy

What could go wrong

Disclosed plainly. Modeled figures across this site are identified as such and are not observed outcomes.

12.1

Regulatory & cross-jurisdictional

LRGN may be classified as a security, financial instrument, commodity or bespoke digital asset, and that view can change. Health data rules differ by corridor, and a counterparty losing its licence can suspend a settlement path without any protocol fault.

12.2

Contracts, circuits & physical oracles

Audited contracts can still hold bugs; circuits rest on soundness assumptions; bridges carry custodial risk bounded by exposure limits. Physical collusion remains the likeliest attack — slashing prices it rather than preventing it — and consumer devices vary in security.

12.3

Liquidity, markets & volatility

Payer funding at modeled levels is unproven at scale. Validator recruitment may lag, incumbents may build competing infrastructure, and thin liquidity or market sentiment can diverge from fundamentals for long periods.

12.4

Health delivery boundaries

The protocol provides coordination, attestation and settlement. It does not practice medicine, diagnose or treat, and does not replace licensed professionals. Clinical protocols are authored by licensed practitioners under their own obligations.

!

Forward-looking statements rest on assumptions that may prove wrong. Nothing here is investment advice, a financial promotion, or an offer or solicitation to buy any token or security in any jurisdiction. Seek independent legal, financial and medical advice.